Other Services HCPCS Code range M1146-M1503

Patients on a therapeutic clinical trial

Patients with recurrence/disease progression

Patients who leave the practice during the follow-up period

Patients who died during the follow-up period

Patients who have germline brca testing completed before diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer

Patients who received germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis

Patients who did not have germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis

Currently on first-line immune checkpoint inhibitors without chemotherapy

Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement

Patients who had a positive pd-l1 biomarker expression test result prior to the initiation of first-line immune checkpoint inhibitor therapy